Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Yue

Showing results (411-420 of 417) with videos related to

Pageof 42
Sort By:
You have reached the last page of results.This site can display upto 417 results.
Nature Communications|May 8, 2026
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trialsWallace Bourgeois, Hannah E Rice, Daniela V Wenge, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Cell Chemical Biology|February 11, 2026
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesisPeter Geon Kim, Christopher B Hergott, Aidan P Miller, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|December 23, 2008
[Clinical features of unexpected sudden death clustered in 7 families in Yunnan Province]Jian Zhang, Guo-qing Shi, Wen-li Huang, et al.
Nature|March 28, 2024
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNFSandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 42

Showing results (411-420 of 417) with videos related to

Sort By:
Pageof 42
You have reached the last page of results.This site can display upto 417 results.
Nature Communications|May 8, 2026
CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trialsWallace Bourgeois, Hannah E Rice, Daniela V Wenge, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Cell Chemical Biology|February 11, 2026
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesisPeter Geon Kim, Christopher B Hergott, Aidan P Miller, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|December 23, 2008
[Clinical features of unexpected sudden death clustered in 7 families in Yunnan Province]Jian Zhang, Guo-qing Shi, Wen-li Huang, et al.
Nature|March 28, 2024
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNFSandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 42